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Abstracts / Pediatric Hematology Oncology Journal 1 (2016) S1eS33 S21Background: Acquired aplastic anemia (AA) is a haematological emer-
gency in children and we have gained enormous knowledge about the
pathogenesis and immune mediated self-destruction of stem cells and
immunosuppressive therapy. Due to its rarity, we have limited data of this
entity, especially, its course and outcome in resource limited countries.
Patientsandmethods: The case recordsof childrenwhohadbeendiagnosed
to have AA since 2002 at our centre were reviewed. The diagnosis of AAwas
made in children with pancytopenia without organomegaly and conﬁrmed
by hypocellular bone marrow showing decreased expression of all three
hematopoietic lineages. Clinical ﬁndings including dysmorphism, thumb
abnormalities, congenital malformations and skin hyperpigmentation were
noted down. Mitomycin C induced chromosomal instability to rule out Fan-
coni anaemia, Ham's test to look for paroxysmal nocturnal haemoglobinuria
and chromosomal analysis to look for complex karyotypic abnormalities seen
in myelodysplastic syndrome were documented in all patients.
After initial stabilization, the option of haematopoietic stem cell trans-
plantation (HSCT) was offered to all those who had matched related do-
nors. If not, immunosuppressive therapy was delivered within twomonths
from diagnosis after the child was infection free. A combination of 40mg/
kg/day of Horse derived antithymocyte globulin (ATGAM) and methyl-
prednisolone at 2 mg/kg/day were started for the ﬁrst 4 days through a
central venous catheter. Oral cyclosporine and G-CSF were started on the
ﬁfth day and since 2015 Eltrombopag was added to the IST regimen.
Revolade and GCSF were continued for about 8 to 12 weeks and cyclo-
sporine from 6 to 12 months. All patient received Voriconazole and
Acyclovir prophylaxis till neutrophil recovery to 1000.
Results: A total of 109 children had been diagnosed as AA, of whom, 42
had acquired AA. Themean age of childrenwith acquired AAwas 8.16 years
(2-15 yrs). Boys were twice more commonly affected (ratio M: F ¼ 2:1).
Details are listed in table 1.
Of the 41, 21 underwent HSCT as they had fully matched related donor and
20 children received IST. Of the 20 children who received ATG, 10 children
(70%) had complete remission in a median duration of 78 days. Two of the
three non responders were treated with second IST and all three succumbed
to the illness. One child developed acute myeloid leukaemia after achieving
partial remission and was salvaged with HSCT, and 1 more non responder
had an unrelated HSCT and is doing well. One child has suffered a relapse
after a durable remission of over 18 months off immunosuppression. The 21
children who have been transplanted have an overall survival rate of 77 %.
Conclusion: Immunosuppressive regimen including Horse ATGAM,
Methyl prednisolone, Cyclosporine, GCSF and Eltrombopag along with
adequate and meticulous supportive care including neutropenic care,
prompt infection management and the use of irradiated and leukode-
pleted blood products results in a 70% response rate and should be offered
to all children with aplastic anaemia with no matched family donor. The
addition of Elthrombopag has resulted in early recovery of all three cell
lines and must be added to the IST protocol in children.Table 1
Clinical features & treatment outcome in Pediatric Aplastic anemia, n¼41
S. No Parameter Results
1. Mean age at presentation 8.16 year
2. Severity at presentation
Severe 41%
Very severe 54%
3. Children required >20 transfusions
prior to presentation
31.7%
4. Karyotypic abnormalities
Partial trisomy 10,14 & Trisomy 7 1
Mitomycin-C rest Equivocal in 1
Negative in others
Ham's test Negative in all
5. Treatment
1. ATG group 20
Survival 16
Complete Response 14
Second IST 2 (expired)
Salvage BMT 2
2. BMT group 21
Survival 16
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IS SERUM FERRITIN A RELIABLE MARKER FOR EVALUATION OF
CARDIAC AND HEPATIC IRON OVERLOAD IN PATIENTS WITH b-
THALASSEMIA MAJOR?
Ankita Pandey, Arijita Chatterjee, Reshma Nevgi, Amit Jain, Prakruthi
Kaushik, Sujata Sharma, Ratna Sharma, Mamta Manglani.
Background: Regular packed red cell transfusions, which is the mainstay
of therapy in thalassemia major, leads to iron overload. This requires
frequent monitoring, thereby instituting appropriate treatment and pre-
venting its associated complications. Iron overload-induced cardiomyop-
athy is reversible if intensive chelation therapy is instituted on time. Early
detection of myocardial iron deposition is imperative to prevent cardiac
complications known with iron overload. Conventionally, serum ferritin
has been used to monitor iron overload in these children. But there have
been recent studies, which have shown that T2* MRI is a better tool for
cardiac and liver iron overload in comparison with serum ferritin. We
analyzed our data to verify this correlation in our patients.
Aims and objectives: To study the correlation between serum ferritin and
T2*MRI for assessment of cardiac and hepatic iron overload in patients of
b-Thalassemia Major.
Materials andmethods: It was a retrospective, cross sectional, descriptive
study which analyzed records of 52patients with transfusion dependent b-
Thalassemia major in the Thalassemia day care centre at our institution.
Inclusion Criteria: Children with transfusion dependent b-thalassemia
major above 6 years of age in whomserum ferritin and T2*MRI were per-
formed at least within 3 months of each other.
Exclusion criteria: Any child withHepatitis B, Hepatitis C and HIV
infection.
Methodology: Demographic data, serum ferritin during last 3 months and
T2*MRI results (which was taken as the gold standard for iron overload)
were retrieved from the records.Standard deﬁnitions of severity of iron
overload for liver and heart on T2* MRI were used for comparisons (Liver:
normal > 6.3ms, mild - 2.8-6.3ms, moderate - 1.4-2.7ms, severe <1.4ms,
Cardiac: normal >20ms, mild - 14 e 20ms, moderate - 10 e 14ms, severe
<10ms.).Statistical analysis was done using Fisher's Exact test and ANOVA
test.
Results: A total of 52 patients were enrolled in the study.Their ages
ranged from 6 years to 22, with a median of 8.5yrs .31 were males and 21
were females. On the basis of T2* MRI values, patients were divided into
none, mild, moderate and severe hepatic and cardiac iron overload. He-
patic iron overload in our patients was as follows: none e 5 (9.6%), mild e
14 (26.9%), moderate e 10 (19.2%), severe e 23 (44.2%) and cardiac iron
overload as follows: none e 36 (69.2%), mild e 12 (23.0%), moderate e 3
(5.7%), severe e 1 (1.9%). When correlating serum ferritin below and
above 2000 ng/ml with the severity of iron overload on T2*MRI, therewas
no signiﬁcant association between serum ferritin levels and degree of iron
overload in cardiac as well as liver MRI (p ¼ 0.92 for cardiac iron overload
and p ¼ 0.39 for liver iron overload).Our results also show that there was
no signiﬁcant correlation between serum ferritin and cardiac MRIﬁndings
(p ¼ 0.725) or between ferritin and hepatic MRI (p ¼ 0.910). Also no
signiﬁcant correlation was observed between cardiac and hepatic MRI
values (p ¼ 0.07).
Conclusion: The present study concludes that there is no correlation be-
tween serum ferritin level and T2*MRI for cardiac as well as liver iron
overload. Hence, serum ferritin should not be the sole marker for evalu-
ating iron overload. Also, cardiac and hepatic iron overload on T2* MRI did
not correlate with each other. This suggests that individual organ evalua-
tion by T2* MRI may be the way ahead for effective prevention of com-
plications by appropriate chelation.
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